NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

伴隨式診斷開發服務的全球市場:2020年∼2030年

Companion Diagnostics Development Services Market, 2020-2030

出版商 Roots Analysis 商品編碼 923511
出版日期 內容資訊 英文 350 Pages
商品交期: 最快1-2個工作天內
價格
伴隨式診斷開發服務的全球市場:2020年∼2030年 Companion Diagnostics Development Services Market, 2020-2030
出版日期: 2020年01月31日內容資訊: 英文 350 Pages
簡介

個體化醫療,在醫療部門內帶來了模式轉移。可是,特定疾病相關的分子標記配合的治療方法上,醫生為了認識患者特定的遺傳特徵,進行資訊為基礎的治療相關的決策,恰當的伴隨式診斷是必須的。

本報告提供全球伴隨式診斷開發服務市場相關調查分析,目前市場情形與未來的機會相關的系統性資訊。

目錄

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 市場形勢

  • 章概要
  • 伴隨式診斷服務供應商:整體市場形勢
  • 伴隨式診斷服務供應商:開發業者情勢

第5章 企業簡介

  • 章概要
  • 北美的主要企業
    • Asuragen
    • Covance
    • Geneuity
    • MD Biosciences
    • ResearchDx
  • 歐洲的企業
    • Almac Diagnostic Services
    • Leica Biosystems
    • R-Biopharm
    • Tepnel Pharma Services
  • 亞太地區的主要企業
    • BARD1 Life Sciences
    • BioMarCare Technologies
    • Gencurix
    • Macrogen

第6章 夥伴關係與合作

  • 章概要
  • 夥伴關係模式
  • 夥伴關係與合作的清單

第7章 合作夥伴的可能性分析

  • 章概要
  • 範圍與手法
  • 評分標準主要的前提條件
  • 伴隨式診斷服務供應商的合作夥伴的可能性:阿茲海默症
  • 伴隨式診斷服務供應商的合作夥伴的可能性:乳癌
  • 伴隨式診斷服務供應商的合作夥伴的可能性:大腸癌症
  • 伴隨式診斷服務供應商的合作夥伴的可能性:HIV
  • 伴隨式診斷服務供應商的合作夥伴的可能性:肺癌症
  • 伴隨式診斷服務供應商的合作夥伴的可能性:NASH/NAFLD
  • 伴隨式診斷服務供應商的合作夥伴的可能性:卵巢癌症
  • 伴隨式診斷服務供應商的合作夥伴的可能性:前列腺癌症

第8章 企業的競爭分析

  • 章概要
  • 手法
  • 前提條件與主要參數
  • 企業的競爭分析

第9章 相關利益者的需求分析

  • 章概要
  • 伴隨式診斷:各種相關利益者的需求
  • 各種相關利益者的需求比較

第10章 價值鏈分析

  • 章概要
  • 伴隨式診斷的價值鏈:成本分佈
  • 伴隨式診斷的開發營運:主要的成本貢獻業者
  • 伴隨式診斷的共同開發營運:主要的成本貢獻業者

第11章 癌症生物標記臨床研究:大型製藥企業預測

  • 章概要
  • 手法
  • 臨床實驗分析
  • 生物標記中心的實驗的累積分佈:各登記年度
  • 最受歡迎的適應症的生物標記中心的實驗分析
  • 生物標記中心的實驗分析:各開發階段
  • 生物標記中心的實驗分析:各贊助商
  • 生物標記中心的實驗分析:各募集情況
  • 生物標記中心的實驗分析:各治療設計
  • 生物標記中心的實驗分析:各地區等

第12章 市場預測、機會分析

  • 章概要
  • 主要的前提條件與預測手法
  • 全球伴隨式診斷服務市場
  • 北美的伴隨式診斷服務市場
  • 歐洲的伴隨式診斷服務市場
  • 亞洲的伴隨式診斷服務市場
  • 其他地區的伴隨式診斷服務市場

第13章 執行考察

第14章 結論

第15章 附錄1:表格總計資料

第16章 附錄2:企業和組織的清單

目錄

Example Insights:

The rise in interest in this field is reflected in the number of partnerships established in the recent past, involving both international and indigenous stakeholders, and focused on a variety of end objectives.

Overview:

Personalized medicine has brought about a paradigm shift within the healthcare sector. However, therapies tailored to specific disease-related molecular signatures require appropriate companion diagnostics in order to make physicians aware of patients' unique genetic profiles, enabling them to make informed treatment related decisions. In fact, a clinical study of nearly 200 unique pharmacological interventions, which were evaluated across more than 670 clinical trials, suggests that the likelihood of a lead compound passing through various phases of clinical development and eventually getting approved is only 11%. The same study pointed out that using disease-specific biomarker information (indicative of susceptibility to particular types of therapeutics) to recruit patients for clinical research has been associated with a manifold increase in trial success rates. In addition, it is worth noting that companion diagnostics guided drug development efforts have demonstrated to effectively reduce clinical trial costs by almost 60%.

Given the aforementioned advantages, the industry is gradually shifting from the traditional, one-drug-for-all, paradigm to using tailored pharmacological interventions. This shift is subsequently expected to increase the demand for companion diagnostics. However, given the complexity associated with the co-development of a drug and a corresponding companion diagnostic test, pharmaceutical developers have shown preference to outsource the diagnostics development operations. In fact, nearly 80% of the companies are known to rely on external diagnostics developers for companion diagnostics development, mostly owing to the lack of in-house expertise. As a result, numerous contract service providers are striving to expand their respective portfolios and developing the capabilities to offer end-to-end services to sponsor companies in this domain. Amidst tough competition, the availability of cutting-edge tools and technologies (such as in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR)) has emerged as a differentiating factor and is likely to grant a competitive advantage to certain service providers over other players in the industry.

Scope of the Report:

The ‘Companion Diagnostics Development Services Market, 2020-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of diagnostic development services over the next decade. It features an in-depth analysis, highlighting the capabilities of the various stakeholders in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of companies offering companion diagnostics services, including information on the type of services offered, type of analytical technique used and regulatory certifications / accreditations, and other company-specific details (such as year of establishment, company size and geographical location).
  • Tabulated profiles of companion diagnostics service providers (shortlisted on the basis of the number of services offered), featuring an overview of the company, its financial information (if available), and companion diagnostics-related service portfolio details. In addition, each profile includes a list of the likely strategies that may be adopted by these players to support future growth.
  • An analysis of the partnerships and collaborations pertaining to companion diagnostics services from 2017 to 2019, featuring a detailed set of analyses based on various parameters, such as the type of partnership, year of partnership, analytical technique used and the most active players.
  • A list of stakeholders generated based on a detailed analysis of a set of relevant parameters (namely number of clinical trials sponsored by a developer and the time to market for proprietary personalized medicine products), which are anticipated to partner with companion diagnostics services providers in the foreseen future.
  • A detailed competitiveness analysis of companion diagnostics services providers, taking into consideration the supplier power (based on the year of establishment of developer) and key specifications, such as portfolio strength, type of available technology platform, number of deals signed between 2017-2019.
  • A comparative analysis of the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain.
  • A discussion on various steps of the development operations, namely research and development, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing / sales activities, of a companion diagnostic and the cost requirements across each of the aforementioned stages.
  • An analysis of completed, ongoing and planned clinical trials featuring disease-specific biomarkers. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, key indications, type of therapy, biomarkers evaluated, enrolled patient population and regional distribution of trials.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for companion diagnostic services providers, over the next decade. Based on multiple parameters, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] key services offered (biomarker discovery, assay development, clinical validation, analytical validation and manufacturing), [B] analytical techniques used (ISH, IHC, NGS, PCR and others), and [C] key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of discussions held with the following industry stakeholders:

  • Pablo Ortiz (Chief Executive Officer, OWL Metabolomics)
  • Paul Kortschak (Senior Vice President, Novodiax)
  • Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the current state of the market for companion diagnostics services, in the short-mid-term and long term.

Chapter 3 is an introductory chapter that highlights the importance of companion diagnostics in relation to personalized medicine. The chapter describes the approaches used to develop a companion diagnostic, along with information on the various analytical techniques that form the basis for such tests. It also provides details on key market drivers and challenges within this industry.

Chapter 4 provides a list of companion diagnostics services providers. It includes information on the companion diagnostics-related service portfolio (biomarker research / identification, feasibility studies, assay development, analytical validation, clinical validation, regulatory assistance, commercialization, manufacturing and other supporting services), analytical techniques (flow cytometry, in situ hybridization (ISH), immunohistochemistry (IHC), micro array, next generation sequencing (NGS), polymerase chain reaction (PCR), and sanger sequencing), regulatory certification / accreditation, along with the information of service provider year of establishment, company size and geographical location.

Chapter 5 provides tabulated profiles of some of the leading stakeholders in this field (shortlisted on the basis of the strength of product portfolio). Each profile presents a brief overview of the company, financial information (if available) and an informed future outlook.

Chapter 6 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players since 2017. It includes a brief description of various types of partnership models that have been adopted by stakeholders in this domain. It also includes a schematic representation that showcases the companies that have established the maximum number of alliances, highlighting key analytical techniques and disease indications.

Chapter 7 presents the of stakeholders that are anticipated to partner with companion diagnostics services providers in the foreseen future based on a detailed analysis of relevant parameters, namely, number of clinical trials sponsored by a developer and the time to market for proprietary personalized medicine products.

Chapter 8 presents a competitiveness analysis of the companion diagnostics service providers based on supplier power of the developers and portfolio strength. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 9 provides information on the needs of different stakeholders (drug developers, diagnostic developers, testing laboratories, physicians, payers and patients) involved in this domain. The chapter qualitatively assesses the various companion diagnostics-related needs of these stakeholders, highlighting their respective perspectives regarding the importance of each need.

Chapter 10 presents a value chain analysis featuring a discussion on various steps of the development operations, namely R&D development, clinical assessment of the product, manufacturing and assembly, payer negotiation and marketing activities, of a companion diagnostics and the cost requirements across each of the aforementioned stages.

Chapter 11 provides a detailed clinical trial analysis of completed, ongoing and planned studies, related to disease-specific biomarkers, being sponsored by the top pharmaceutical players. The analysis highlights the key trends associated with these clinical studies across various parameters, such as trial start year, trial status, phase of development, key indications, type of therapy, biomarkers evaluated, enrolled patient population and regional distribution of trials

Chapter 12 features a comprehensive market forecast analysis, highlighting the likely growth of companion diagnostics services market till the year 2030. We have provided inputs on the likely distribution of the opportunity based on the services offered (biomarker discovery, feasibility studies, assay development, clinical validation, analytical validation and manufacturing), assay techniques (in situ hybridization (ISH), immune histochemistry (IHC), next generation sequencing (NGS), polymerase chain reaction (PCR) and others), and key geographical regions (North America, Europe, Asia and rest of the world).

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of the companion diagnostics industry.

Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with Pablo Ortiz (Chief Executive Officer, OWL Metabolomics), Paul Kortschak (Senior Vice President, Novodiax) and Lawrence M. Weiss (Chief Scientific Officer, NeoGenomics Laboratories).

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Evolution of Personalized Medicine
  • 3.3. Overview of Companion Diagnostics
    • 3.3.1. Development of Companion Diagnostics
    • 3.3.2. Analytical Techniques Used in Companion Diagnostic Tests
      • 3.3.2.1. Immunohistochemistry
      • 3.3.2.2. In situ Hybridization
      • 3.3.2.3. Polymerase Chain Reaction
      • 3.3.2.4. DNA Sequencing / Next Generation Sequencing
    • 3.3.3. Advantages of Companion Diagnostics
  • 3.4. Applications of Companion Diagnostics across Different Therapeutic Areas
    • 3.4.1. Oncology
    • 3.4.2. Infectious Diseases
    • 3.4.3. Neurological Disorders
  • 3.5. Regulatory Review and Approval Process for Companion Diagnostics
  • 3.6. Existing Challenges
  • 3.7. Future Roadmap

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Companion Diagnostics Service Providers: Overall Market Landscape
    • 4.2.1 Analysis by Type of Service Offered
    • 4.2.2. Analysis by Type of Analytical Technique
    • 4.2.3. Analysis by Regulatory Accreditation / Certification
    • 4.2.4. Analysis by Type of End User
  • 4.3. Companion Diagnostics Service Providers: Developer Landscape
    • 4.3.1 Analysis by Year of Establishment
    • 4.3.2 Analysis by Company Size
    • 4.3.3 Analysis by Geographical Location
    • 4.3.4 Grid Representation: Analysis by Type of Service Offered, Company Size, and Geographical Location
    • 4.3.5 World Map Representation: Analysis by Geography

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. Key Players in North America
    • 5.2.1. Asuragen
      • 5.2.1.1. Recent Developments and Future Outlook
    • 5.2.2. Covance
      • 5.2.2.1. Recent Developments and Future Outlook
    • 5.2.3. Geneuity
      • 5.2.3.1. Recent Developments and Future Outlook
    • 5.2.4. MD Biosciences
      • 5.2.4.1. Recent Developments and Future Outlook
    • 5.2.5. ResearchDx
      • 5.2.5.1. Recent Developments and Future Outlook
  • 5.3. Players in Europe
    • 5.3.1. Almac Diagnostic Services
      • 5.3.1.1. Recent Developments and Future Outlook
    • 5.3.2. Leica Biosystems
      • 5.3.2.1. Recent Developments and Future Outlook
    • 5.3.3. R-Biopharm
      • 5.3.3.1. Recent Developments and Future Outlook
    • 5.3.4. Tepnel Pharma Services
      • 5.3.4.1. Recent Developments and Future Outlook
  • 5.4. Key Players in Asia-Pacific
    • 5.4.1. BARD1 Life Sciences
      • 5.4.1.1. Recent Developments and Future Outlook
    • 5.4.2. BioMarCare Technologies
      • 5.4.2.1. Recent Developments and Future Outlook
    • 5.4.3. Gencurix
      • 5.4.3.1. Recent Developments and Future Outlook
    • 5.4.4. Macrogen
      • 5.4.4.1. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS

  • 6.1 Chapter Overview
  • 6.2 Partnership Models
  • 6.3 List of Partnerships and Collaborations
    • 6.3.1 Analysis by Year of Partnership
    • 6.3.2 Analysis by Type of Partnership
    • 6.3.3 Analysis by Type of Analytical Technique
    • 6.3.4 Analysis by Type of Therapeutic Area
    • 6.3.5 Analysis by Year of Partnership and Type of Partner
    • 6.3.6 Analysis by Type of Partnership and Type of Partner
    • 6.3.7 Most Active Players: Analysis by Number of Partnerships
    • 6.3.8 Popular Analytical Techniques: Analysis by Number of Partnerships
    • 6.3.9 Regional Analysis
    • 6.3.10 Intercontinental and Intracontinental Agreements

7. LIKELY PARTNER ANALYSIS

  • 7.1. Chapter Overview
  • 7.2. Scope and Methodology
  • 7.3. Scoring Criteria and Key Assumptions
  • 7.4. Likely Partners for Companion Diagnostics Service Providers: Alzheimer's Disease
    • 7.4.1. Companies Working on the Amyloid Beta Biomarker
      • 7.4.1.1. World Map Representation: Amyloid Beta Biomarker Focused Clinical Trials
    • 7.4.2. Companies Working on the Tau Biomarker
      • 7.4.2.1. World Map Representation: Tau Biomarker Focused Clinical Trials
  • 7.5. Likely Partners for Companion Diagnostics Service Providers: Breast Cancer
    • 7.5.1. Companies Working on the BRCA Biomarker
      • 7.5.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials
    • 7.5.2. Companies Working on the HER Biomarker
      • 7.5.2.1. World Map Representation: HER Biomarker Focused Clinical Trials
    • 7.5.3. Companies Working on the HR Biomarker
      • 7.5.3.1. World Map Representation: HR Biomarker Focused Clinical Trials
    • 7.5.4. Companies Working on the PD-L1 Biomarker
      • 7.5.4.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials
  • 7.6. Likely Partners for Companion Diagnostics Service Providers: Colorectal Cancer
    • 7.6.1. Companies Working on the BRAF Biomarker
      • 7.6.1.1. World Map Representation: BRAF Biomarker Focused Clinical Trials
    • 7.6.2. Companies Working on the EGFR Biomarker
      • 7.6.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials
    • 7.6.3. Companies Working on the KRAS Biomarker
      • 7.6.3.1. World Map Representation: KRAS Biomarker Focused Clinical Trials
    • 7.6.4. Companies Working on the MSI Biomarker
      • 7.6.4.1. World Map Representation: MSI Biomarker Focused Clinical Trials
    • 7.6.5. Companies Working on the NRAS Biomarker
      • 7.6.5.1. World Map Representation: NRAS Biomarker Focused Clinical Trials
  • 7.7. Likely Partners for Companion Diagnostic Service Providers: HIV
    • 7.7.1. Companies Working on the CCR5 Biomarker
      • 7.7.1.1. World Map Representation: CCR5 Biomarker Focused Clinical Trials
  • 7.8. Likely Partners for Companion Diagnostics Service Providers: Lung Cancer
    • 7.8.1. Companies Working on the ALK Biomarker
      • 7.8.1.1. World Map Representation: ALK Biomarker Focused Clinical Trials
    • 7.8.2. Companies Working on the EGFR Biomarker
      • 7.8.2.1. World Map Representation: EGFR Biomarker Focused Clinical Trials
    • 7.8.3. Companies Working on the PD-L1 Biomarker
      • 7.8.3.1. World Map Representation: PD-L1 Biomarker Focused Clinical Trials
    • 7.8.4. Companies Working on the ROS Biomarker
      • 7.8.4.1. World Map Representation: ROS Biomarker Focused Clinical Trials
  • 7.9. Likely Partners for Companion Diagnostics Service Providers: NASH / NAFLD
    • 7.9.1. Companies Working on the AST Biomarker
      • 7.9.1.1. World Map Representation: AST Biomarker Focused Clinical Trials
  • 7.10. Likely Partners for Companion Diagnostics Service Providers: Ovarian Cancer
    • 7.10.1. Companies Working on the BRCA Biomarker
      • 7.10.1.1. World Map Representation: BRCA Biomarker Focused Clinical Trials
    • 7.10.2. Companies Working on the CA-125 Biomarker
      • 7.10.2.1. World Map Representation: CA-125 Biomarker Focused Clinical Trials
  • 7.11. Likely Partners for Companion Diagnostics Service Providers: Prostate Cancer
    • 7.11.1. Companies Working on the PTEN Biomarker
      • 7.11.1.1. World Map Representation: PTEN Biomarker Focused Clinical Trials

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1 Chapter Overview
  • 8.2 Methodology
  • 8.3 Assumptions and Key Parameters
  • 8.4 Company Competitiveness Analysis
    • 8.4.1 Companion Diagnostics Service Providers based in North America
    • 8.4.2 Companion Diagnostics Service Providers based in Europe
    • 8.4.3 Companion Diagnostics Service Providers based in Asia Pacific / RoW

9. STAKEHOLDER NEEDS ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Companion Diagnostics: Needs of Different Stakeholders
  • 9.3. Comparison of Needs of Various Stakeholders
    • 9.3.1. Needs of Drug Developers
    • 9.3.2. Needs of Companion Diagnostics Developers
    • 9.3.3. Needs of Regulatory Authorities
    • 9.3.4. Needs of Testing Laboratories
    • 9.3.5. Needs of Payers / Insurance Providers
    • 9.3.6. Needs of Physicians
    • 9.3.7. Needs of Patients

10. VALUE CHAIN ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Companion Diagnostics Value Chain: Cost Distribution
    • 10.2.1. Research and Product Development
    • 10.2.2. Manufacturing and Assembly
    • 10.2.3. Clinical Trials, FDA Approval and Other Administrative Tasks
    • 10.2.4. Payer Negotiation and KOL Engagement
    • 10.2.5. Marketing and Sales
  • 10.3. Companion Diagnostics Development Operations: Key Cost Contributors
  • 10.4. Companion Diagnostics Co-Development Operations: Key Cost Contributors

11. CLINICAL RESEARCH ON CANCER BIOMARKERS: BIG PHARMA PERSPECTIVE

  • 11.1. Chapter Overview
  • 11.2. Methodology
  • 11.3. Clinical Trial Analysis
    • 11.3.1. List of Likely Drug Candidates for IVD Developers
  • 11.4. Cumulative Distribution of Biomarker Focused Trials by Registration Year, 2016-2019
    • 11.4.1. Analysis of Trials for Most Popular Biomarkers
    • 11.4.2. Analysis of Trials for Moderately Popular Biomarkers
    • 11.4.3. Analysis of Trials for Less Popular / Preliminary Stage Biomarkers
    • 11.4.4. Other Emerging Biomarkers: Word Cloud
    • 11.4.5. Cumulative Distribution of Trials of the Most Popular Biomarkers by Registration Year
    • 11.4.6. Cumulative Distribution of Trials of the Moderately Popular Biomarkers by Registration Year
    • 11.4.7. Cumulative Distribution of Trials of the Less Popular Biomarkers by Registration Year
  • 11.5. Analysis of Biomarker Focused Trials for Most Popular Indications
    • 11.5.1. Analysis of Trials for Moderately Popular Indications
    • 11.5.2. Analysis of Trials for Less Popular and Other Indications
    • 11.5.3. Other Emerging Indications: Word Cloud
    • 11.5.4. Cumulative Distribution of Trials of the Most Popular Indications by Registration Year
    • 11.5.5. Cumulative Distribution of Trials of the Moderately Popular Indications by Registration Year
    • 11.5.6. Cumulative Distribution of Trials of the Less Popular / Preliminary Stage Indications by Registration Year
  • 11.6. Analysis of Biomarker Focused Trials by Phase of Development
    • 11.6.1. Analysis of Trials of the Most Popular Biomarkers
    • 11.6.2. Analysis of Trials of the Moderately Popular Biomarkers
    • 11.6.3. Analysis of Trials of the Less Popular and Other Biomarkers
    • 11.6.4. Analysis of Trials of the Most Popular Indications
    • 11.6.5. Analysis of Trials of the Moderately Popular Indications
    • 11.6.6. Analysis of Trials of the Less Popular and Other Indications
  • 11.7. Analysis of Biomarker Focused Trials by Sponsor
    • 11.7.1. Analysis of Trials of the Most Popular Biomarkers
    • 11.7.2. Analysis of Trials of the Moderately Popular Biomarkers
    • 11.7.3. Analysis of Trials of the Most Popular Indications
    • 11.7.4. Analysis of Trials of the Moderately Popular Indications
  • 11.8. Analysis of Biomarker Focused Trials by Recruitment Status
  • 11.9. Analysis of Biomarker Focused Trials by Therapy Design
  • 11.10. Analysis of Biomarker Focused Trials by Geography
    • 11.10.1. Analysis of Trials by Phase of Development and Recruitment Status
  • 11.11. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Most Popular Indications
  • 11.12. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Moderately Popular Indications
  • 11.13. Clinical Trials Summary: Analysis of Biomarker Focused Trials by Preliminary Stage Indications

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Forecast Methodology
  • 12.3. Global Companion Diagnostics Services Market, 2020-2030
    • 12.3.1. Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2020-2030
    • 12.3.2. Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique, 2020-2030
    • 12.3.3. Global Companion Diagnostics Services Market: Distribution by Region, 2020-2030
  • 12.4. Companion Diagnostics Services Market in the North America, 2020-2030
    • 12.4.1. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030
    • 12.4.2. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030
  • 12.5. Companion Diagnostics Services Market in Europe, 2020-2030
    • 12.5.1. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030
    • 12.5.2. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030
  • 12.6. Companion Diagnostics Services Market in Asia, 2020-2030
    • 12.6.1. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030
    • 12.6.2. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030
  • 12.7. Companion Diagnostics Services Market in Rest of the World, 2020-2030
    • 12.7.1. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030
    • 12.7.2. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030

13. EXECUTIVE INSIGHTS

  • 13.1. Chapter Overview
  • 13.2. OWL Metabolomics
    • 13.2.1. Company Snapshot
    • 13.2.2. Interview Transcript: Pablo Ortiz, Chief Executive Officer
  • 13.3. Novodiax
    • 13.3.1 Company Snapshot
    • 13.3.2. Interview Transcript: Paul Kortschak, Senior Vice President

14. CONCLUDING REMARKS

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

  • Figure 3.1. Evolution of Personalized Medicine, 2012-2017
  • Figure 3.2. Preclinical Development of Biomarker-based Targeted Therapies
  • Figure 3.3. Role of Companion Diagnostics in Clinical Trials
  • Figure 3.4. Companion Diagnostics: Key Advantages
  • Figure 3.5. Companion Diagnostics: Primary Development-related Challenges
  • Figure 3.6. Companion Diagnostics: Market Drivers and Constraints
  • Figure 4.1. Companion Diagnostics Service Providers: Distribution by Type of Service Offered
  • Figure 4.2. Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique
  • Figure 4.3. Companion Diagnostics Service Providers: Distribution by Type of Regulatory Accreditation / Certification
  • Figure 4.4. Companion Diagnostics Service Providers: Distribution by Type of End User
  • Figure 4.5. Companion Diagnostics Service Providers: Distribution by Year of Establishment
  • Figure 4.6. Companion Diagnostics Service Providers: Distribution by Company Size
  • Figure 4.7. Companion Diagnostics Service Providers: Distribution by Geographical Location
  • Figure 4.8. Grid Representation: Distribution by Type of Service Offered, Company Size, and Geographical Location
  • Figure 4.9. World Map Representation: Analysis by Geography
  • Figure 6.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2019
  • Figure 6.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 6.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2019.
  • Figure 6.4. Partnerships and Collaborations: Distribution by Type of Analytical Technique and Type of Partnership
  • Figure 6.5. Partnerships and Collaborations: Distribution by Type of Therapeutic Area and Type of Partnership
  • Figure 6.6. Partnerships and Collaborations: Year-wise Trend for Type of Partner
  • Figure 6.7. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 6.8. Most Active Players: Distribution by Number of Partnerships
  • Figure 6.9. Partnership and Collaborations: Regional Distribution
  • Figure 6.10. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Figure 7.1. World Map Representation: Distribution of Amyloid Beta Biomarker Focused Clinical Trials
  • Figure 7.2. World Map Representation: Distribution of Tau Biomarker Focused Clinical Trials
  • Figure 7.3. World Map Representation: Distribution of BRCA Focused Clinical Trials
  • Figure 7.4. World Map Representation: Distribution of HER Focused Clinical Trials
  • Figure 7.5. World Map Representation: Distribution of HR Focused Clinical Trials
  • Figure 7.6. World Map Representation: Distribution of PD-L1 Focused Clinical Trials
  • Figure 7.7. World Map Representation: Distribution of BRAF Focused Clinical Trials
  • Figure 7.8. World Map Representation: Distribution of EGFR Focused Clinical Trials
  • Figure 7.9. World Map Representation: Distribution of KRAS Focused Clinical Trials
  • Figure 7.10. World Map Representation: Distribution of MSI Focused Clinical Trials
  • Figure 7.11. World Map Representation: Distribution of NRAS Focused Clinical Trials
  • Figure 7.12. World Map Representation: Distribution of CCR5 Focused Clinical Trials
  • Figure 7.13. World Map Representation: Distribution of ALK Focused Clinical Trials
  • Figure 7.14. World Map Representation: Distribution of EGFR Focused Clinical Trials
  • Figure 7.15. World Map Representation: Distribution of PD-L1 Focused Clinical Trials
  • Figure 7.16. World Map Representation: Distribution of ROS Focused Clinical Trials
  • Figure 7.17. World Map Representation: Distribution of AST Focused Clinical Trials
  • Figure 7.18. World Map Representation: Distribution of BRCA Focused Clinical Trials
  • Figure 7.19. World Map Representation: Distribution of CA-125 Focused Clinical Trials
  • Figure 7.20. World Map Representation: Distribution of PTEN Focused Clinical Trials
  • Figure 8.1. Competitiveness Analysis: Companion Diagnostics Service Providers Based in North America
  • Figure 8.2. Competitiveness Analysis: Companion Diagnostics Service Providers Based in Europe
  • Figure 8.3. Competitiveness Analysis: Companion Diagnostics Service Providers Based in Asia Pacific / RoW
  • Figure 9.1. Stakeholder Needs Analysis: Comparison of Needs of Different Stakeholders
  • Figure 9.2. Stakeholder Needs Analysis: Comparison of Needs of Various Stakeholders Stakeholder Needs Analysis: Comparison of Needs of Various Stakeholders
  • Figure 9.3. Stakeholder Needs Analysis: Comparison of Needs of Companion Diagnostics Stakeholder Needs Analysis: Comparison of Needs of Companion Diagnostics Developers
  • Figure 9.4. Stakeholder Needs Analysis: Needs of Regulatory Authorities
  • Figure 9.5. Stakeholder Needs Analysis: Needs of Testing Laboratories
  • Figure 9.6. Stakeholder Needs Analysis: Needs of Payers / Insurance Providers
  • Figure 9.7. Stakeholder Needs Analysis: Needs of Physicians
  • Figure 9.8. Stakeholder Needs Analysis: Needs of Patients
  • Figure 10.1. Companion Diagnostics Value Chain: Cost Distribution
  • Figure 10.2. Companion Diagnostics Value Chain: Research and Product Development
  • Figure 10.3. Companion Diagnostics Value Chain: Manufacturing and Assembly
  • Figure 10.4. Companion Diagnostics Value Chain: Clinical Trials, FDA Approval and Other Administrative Tasks
  • Figure 10.5. Companion Diagnostics Value Chain: Payer Negotiation and KOL Engagement
  • Figure 10.6. Companion Diagnostics Value Chain: Marketing and Sales
  • Figure 10.7. Companion Diagnostics Development Operations: Key Cost Contributors
  • Figure 10.8. Companion Diagnostics Co-Development Operations: Key Cost Contributors
  • Figure 11.1. Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 11.2. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
  • Figure 11.3. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trials Registration Year
  • Figure 11.4. Clinical Trial Analysis: Distribution of Trials of the Less Popular / Preliminary Stage Biomarkers by Trial Registration Year
  • Figure 11.5. Other Emerging Biomarkers: Word Cloud
  • Figure 11.6. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
  • Figure 11.7. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trial Registration Year
  • Figure 11.8. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Trial Registration Year
  • Figure 11.9. Clinical Trial Analysis: Distribution by Most Popular Indications
  • Figure 11.10. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications
  • Figure 11.11. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Indications
  • Figure 11.12. Less Popular and Other Indications: Word Cloud
  • Figure 11.13. Clinical Trial Analysis: Distribution of Trial of the Most Popular Indications by Trial Registration Year
  • Figure 11.15. Clinical Trial Analysis: Distribution of Trial of the Moderately Popular Indications by Trial Registration Year
  • Figure 11.16. Clinical Trial Analysis: Distribution of Trial of the Less Popular and Other Indications by Trial Registration Year
  • Figure 11.17. Clinical Trial Analysis: Distribution by Trial Phase of Development
  • Figure 11.18. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Phase of Development
  • Figure 11.19. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Phase of Development
  • Figure 11.20. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Phase of Development
  • Figure 11.21. Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Phase of Development
  • Figure 11.22. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Phase of Development
  • Figure 11.23. Clinical Trial Analysis: Distribution of Trials of the Less Popular / Emerging Indications by Phase of Development
  • Figure 11.24. Clinical Trial Analysis: Distribution of Trials by Sponsor
  • Figure 11.25. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Sponsor
  • Figure 11.26. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Sponsor
  • Figure 11.27. Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Sponsor
  • Figure 11.28. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Sponsor
  • Figure 11.29. Clinical Trial Analysis: Distribution by Recruitment Status
  • Figure 11.30. Clinical Trial Analysis: Distribution by Therapy Design
  • Figure 11.31. Clinical Trial Analysis: Distribution by Geography
  • Figure 11.32. Clinical Trial Analysis: Distribution by Enrolled Patient Population
  • Figure 11.33. Clinical Trial Analysis: Distribution of Trials of the Lung Cancer by Affiliated Biomarkers
  • Figure 11.34. Clinical Trial Analysis: Distribution of Trials of the Breast Cancer by Affiliated Biomarkers
  • Figure 11.35. Clinical Trial Analysis: Distribution of Trials of the Lymphoma by Affiliated Biomarkers
  • Figure 11.36. Clinical Trial Analysis: Distribution of Trials of the Ovarian Cancer by Affiliated Biomarkers
  • Figure 11.37. Clinical Trial Analysis: Distribution of Trials of the Prostate Cancer by Affiliated Biomarkers
  • Figure 11.38. Clinical Trial Analysis: Distribution of Trials of the Melanoma by Affiliated Biomarkers
  • Figure 11.39. Clinical Trial Analysis: Distribution of Trials of the Colon / Colorectal Cancer by Affiliated Biomarkers
  • Figure 11.40. Clinical Trial Analysis: Distribution of Trials of the Head and Neck Cancer by Affiliated Biomarkers
  • Figure 12.1. Global Companion Diagnostics Services Market, 2020-2030(USD Billion)
  • Figure 12.2. Global Companion Diagnostics Services Market: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Figure 12.3. Global Companion Diagnostics Services Market: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)
  • Figure 12.4. Global Companion Diagnostics Services Market: Distribution by Region, 2020-2030(USD Billion)
  • Figure 12.5. Companion Diagnostics Services Market in the North America, 2020-2030(USD Billion)
  • Figure 12.6. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Figure 12.7. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)
  • Figure 12.8. Companion Diagnostics Services Market in Europe, 2020-2030(USD Billion)
  • Figure 12.9. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Figure 12.10. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)
  • Figure 12.11. Companion Diagnostics Services Market in Asia, 2020-2030(USD Billion)
  • Figure 12.12. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Figure 12.13. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)
  • Figure 12.14. Companion Diagnostics Services Market in Rest of the World, 2020-2030(USD Billion)
  • Figure 12.15. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Figure 12.16. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030

List of Tables

  • Table 4.1. Companion Diagnostics Service Providers: Information on Type of Service Offered
  • Table 4.2. Companion Diagnostics Service Providers: Information on Type of Analytical Techniques
  • Table 4.3. Companion Diagnostics Service Providers: Additional Information(Regulatory Certification / Accreditation and Type of End User)
  • Table 5.1. Companion Diagnostic Service Providers: List of Profiled Companies
  • Table 5.2. Asuragen: Company Snapshot
  • Table 5.3. Asuragen: Recent Developments and Future Outlook
  • Table 5.4. Covance: Company Snapshot
  • Table 5.5. Covance: Recent Developments and Future Outlook
  • Table 5.6. Geneuity: Company Snapshot
  • Table 5.7. Geneuity: Recent Developments and Future Outlook
  • Table 5.8. MD BIOSCIENCES: Company Snapshot
  • Table 5.9. MD BIOSCIENCES: Recent Developments and Future Outlook
  • Table 5.10. ResearchDx: Company Snapshot
  • Table 5.11. ResearchDx: Recent Developments and Future Outlook
  • Table 5.12. Almac Diagnostic Services: Company Snapshot
  • Table 5.13. Almac Diagnostic Services: Recent Developments and Future Outlook
  • Table 5.14. Leica Biosystems: Company Snapshot
  • Table 5.15. Leica Biosystems: Recent Developments and Future Outlook
  • Table 5.16. R-Biopharm: Company Snapshot
  • Table 5.17. R-Biopharm: Recent Developments and Future Outlook
  • Table 5.18. Tepnel Pharma Services: Company Snapshot
  • Table 5.19. Tepnel Pharma Services: Recent Developments and Future Outlook
  • Table 5.20. BARD1 Life Sciences: Company Snapshot
  • Table 5.21. BARD1 Life Sciences: Recent Developments and Future Outlook
  • Table 5.22. BioMarCare: Company Snapshot
  • Table 5.23. BioMarCare Technologies: Recent Developments and Future Outlook
  • Table 5.24. Gencurix: Company Snapshot
  • Table 5.25. Gencurix: Recent Developments and Future Outlook
  • Table 5.26. Macrogen: Company Snapshot
  • Table 5.27. Macrogen: Recent Developments and Future Outlook
  • Table 6.1. Companion Diagnostic Service Providers: Partnerships and Collaborations, 2014-2019
  • Table 7.1. Companies Working on the Amyloid Beta Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.2. Companies Working on the Tau Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.3. Companies Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.4. Companies Working on the HER Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.5. Companies Working on the HR Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.6. Companies Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.7. Companies Working on the BRAF Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.8. Companies Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.9. Companies Working on the KRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.10. Companies Working on the MSI Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.11. Companies Working on the NRAS Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.12. Companies Working on the CCR5 Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.13. Companies Working on the ALK Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.14. Companies Working on the EGFR Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.15. Companies Working on the PD-L1 Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.16. Companies Working on the RET Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.17. Companies Working on the ROS Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.18. Companies Working on the AST Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.19. Companies Working on the BRCA Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.20. Companies Working on the CA-125 Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 7.21. Companies Working on the PTEN Biomarker: Potential Partners for Companion Diagnostic Service Providers
  • Table 11.1. List of Likely Drug Candidates / Potential Collaborators for Diagnostic Developers
  • Table 11.2. List of Biomarkers across Moderately Popular Indications
  • Table 11.3. List of Biomarkers across Emerging Indications
  • Table 16.1. Companion Diagnostics Service Providers: Distribution by Type of Service Offered
  • Table 16.2. Companion Diagnostics Service Providers: Distribution by Type of Analytical Technique
  • Table 16.3. Companion Diagnostics Service Providers: Distribution by Type of Regulatory Accreditation / Certification
  • Table 16.4. Companion Diagnostics Service Providers: Distribution by Type of End User
  • Table 16.5. Companion Diagnostics Service Providers: Distribution by Year of Establishment
  • Table 16.6. Companion Diagnostics Service Providers: Distribution by Company Size
  • Table 16.7. Companion Diagnostics Service Providers: Distribution by Geographical Location
  • Table 16.8. Partnerships and Collaborations: Cumulative Year-wise Trend, 2017-2019
  • Table 16.9. Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 16.10. Partnerships and Collaborations: Year-wise Trend by Type of Partnership 2017-2019.
  • Table 16.11. Partnerships and Collaborations: Distribution by Type of Analytical Technique and Type of Partnership
  • Table 16.12. Partnerships and Collaborations: Distribution by Type of Therapeutic Area and Type of Partnership
  • Table 16.13. Partnerships and Collaborations: Year-wise Trend for Type of Partner
  • Table 16.14. Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 16.15. Most Active Players: Distribution by Number of Partnerships
  • Table 16.16. Partnership and Collaborations: Regional Distribution
  • Table 16.17. Partnerships and Collaborations: Intercontinental and Intracontinental Deals
  • Table 16.18. Companion Diagnostics Value Chain: Cost Distribution
  • Table 16.19. Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 16.20. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
  • Table 16.21. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trials Registration Year
  • Table 16.22. Clinical Trial Analysis: Distribution of Trials of the Less Popular / Preliminary Stage Biomarkers by Trial Registration Year
  • Table 16.23. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Trial Registration Year
  • Table 16.24. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Trial Registration Year
  • Table 16.25. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Trial Registration Year
  • Table 16.26. Clinical Trial Analysis: Distribution by Most Popular Indications
  • Table 16.27. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications
  • Table 16.28. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Indications
  • Table 16.29. Clinical Trial Analysis: Distribution of Trial of the Most Popular Indications by Trial Registration Year
  • Table 16.30. Clinical Trial Analysis: Distribution of Trial of the Moderately Popular Indications by Trial Registration Year
  • Table 16.31. Clinical Trial Analysis: Distribution of Trial of the Less Popular and Other Indications by Trial Registration Year
  • Table 16.32. Clinical Trial Analysis: Distribution by Trial Phase of Development
  • Table 16.33. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Phase of Development
  • Table 16.34. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Phase of Development
  • Table 16.35. Clinical Trial Analysis: Distribution of Trials of the Less Popular and Other Biomarkers by Phase of Development
  • Table 16.36. Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Phase of Development
  • Table 16.37. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Phase of Development
  • Table 16.38. Clinical Trial Analysis: Distribution of Trials of the Less Popular / Emerging Indications by Phase of Development
  • Table 16.39. Clinical Trial Analysis: Distribution of Trials by Sponsor
  • Table 16.40. Clinical Trial Analysis: Distribution of Trials of the Most Popular Biomarkers by Sponsor
  • Table 16.41. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Biomarkers by Sponsor
  • Table 16.42. Clinical Trial Analysis: Distribution of Trials of the Most Popular Indications by Sponsor
  • Table 16.43. Clinical Trial Analysis: Distribution of Trials of the Moderately Popular Indications by Sponsor
  • Table 16.44. Clinical Trial Analysis: Distribution by Recruitment Status
  • Table 16.45. Clinical Trial Analysis: Distribution by Therapy Design
  • Table 16.46. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario, 2020-2030(USD Billion)
  • Table 16.47. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Table 16.48. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)
  • Table 16.49. Global Companion Diagnostics Services Market, Base, Optimistic and Conservative Scenario: Distribution by Region, 2020-2030(USD Billion)
  • Table 16.50. Companion Diagnostics Services Market in the North America, Base, Optimistic and Conservative Scenario, 2020-2030(USD Billion)
  • Table 16.51. Companion Diagnostics Services Market in the North America: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Table 16.52. Companion Diagnostics Services Market in the North America: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)
  • Table 16.53. Companion Diagnostics Services Market in Europe, Base, Optimistic and Conservative Scenario, 2020-2030(USD Billion)
  • Table 16.54. Companion Diagnostics Services Market in Europe: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Table 16.55. Companion Diagnostics Services Market in Europe: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)
  • Table 16.56. Companion Diagnostics Services Market in Asia, Base, Optimistic and Conservative Scenario, 2020-2030(USD Billion)
  • Table 16.57. Companion Diagnostics Services Market in Asia: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Table 16.58. Companion Diagnostics Services Market in Asia: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)
  • Table 16.59. Companion Diagnostics Services Market in Rest of the World, Base, Optimistic and Conservative Scenario, 2020-2030(USD Billion)
  • Table 16.60. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Service Offered, 2020-2030(USD Billion)
  • Table 16.61. Companion Diagnostics Services Market in Rest of the World: Distribution by Type of Analytical Technique, 2020-2030(USD Billion)

Listed Companies

  • 1. 20/20 GeneSystems
  • 2. A&G Pharmaceutical
  • 3. A4PBio
  • 4. Abbott
  • 5. AbbVie
  • 6. Abcam
  • 7. Abnova
  • 8. AccuGenomics
  • 9. Acobiom
  • 10. ACT Genomics
  • 11. Active Motif
  • 12. AdeptBio
  • 13. Adial Pharmaceuticals
  • 14. Admera Health
  • 15. Advanced Cell Diagnostics
  • 16. Agena Bioscience
  • 17. Agendia
  • 18. Agilent Technologies
  • 19. Agiomix
  • 20. Agios Pharmaceuticals
  • 21. AgriGenome Labs
  • 22. AKESOgen
  • 23. Akoya Biosciences
  • 24. Almac Diagnostic Services
  • 25. AltheaDx
  • 26. Amgen
  • 27. Amoy Diagnostics
  • 28. ANGLE
  • 29. Annoroad Gene Technology
  • 30. Applied BioCode
  • 31. ARCA Biopharma
  • 32. ArcherDX
  • 33. Array BioPharma
  • 34. ARUP Laboratories
  • 35. Ascenda Biosciences
  • 36. Aspira Pathlab and Diagnostics
  • 37. Astellas Pharma
  • 38. AstraZeneca
  • 39. Asuragen
  • 40. AurKa Pharma
  • 41. Avant Diagnostics
  • 42. Ayala Pharmaceuticals
  • 43. BARD1 Life Sciences
  • 44. Bayer
  • 45. Beaufort Services
  • 46. Beckman Coulter
  • 47. BeiGene
  • 48. BGI Genomics
  • 49. Biocartis
  • 50. Biocept
  • 51. BioChain
  • 52. Biocrates Life Sciences
  • 53. Biodesix
  • 54. BioFire Diagnostics
  • 55. BioFluidica
  • 56. BioGenex
  • 57. BioIVT
  • 58. Biolidics
  • 59. BioMarCare Technologies
  • 60. BioMarker Strategies
  • 61. Biomarker Technologies
  • 62. bioMérieux
  • 63. Biotron Healthcare
  • 64. BioVendor
  • 65. Bliss Biopharmaceutical
  • 66. Blueprint Medicines
  • 67. Bosch Healthcare Solutions
  • 68. Bristol-Myers Squibb
  • 69. Brooks Automation
  • 70. CANbridge Life Sciences
  • 71. Cancer Genetics
  • 72. Cancer Treatment Centers of America
  • 73. CancerGuide Diagnostics
  • 74. Caprion Biosciences
  • 75. Caris Life Sciences
  • 76. CD Genomics
  • 77. CeGaT
  • 78. Celgene
  • 79. Celldex Therapeutics
  • 80. Cellestis
  • 81. CENTOGENE
  • 82. Chipscreen Biosciences
  • 83. Chronix Biomedical
  • 84. CIRCULOGENE
  • 85. Clarient
  • 86. Clinical Genomics
  • 87. Clinical Reference Laboratory
  • 88. Clovis Oncology
  • 89. Co-Diagnostics
  • 90. Companion Diagnostics Network
  • 91. ConquerX
  • 92. CORE Diagnostics
  • 93. Corgenix
  • 94. Covance
  • 95. Creative Biolabs
  • 96. Curidium Medica
  • 97. Cypher Genomics
  • 98. Cyprotex
  • 99. Daiichi Sankyo
  • 100. Debiopharm Group
  • 101. deCODE genetics
  • 102. Definiens
  • 103. Delee
  • 104. DiaCarta
  • 105. Diaceutics
  • 106. DiaDx
  • 107. Diversigen
  • 108. DNAnexus
  • 109. DRG International
  • 110. Drug Response Dx
  • 111. Eisai
  • 112. EKF Diagnostics
  • 113. Eli Lilly and Company
  • 114. Elypta
  • 115. EMD Serono
  • 116. Empire Genomics
  • 117. Enzo Biochem
  • 118. Eone-Diagnomics Genome Center
  • 119. Epigenomics
  • 120. Epizyme
  • 121. Eurofins
  • 122. European Network for Gynaecological Oncological Trial groups(ENGOT)
  • 123. European Organization for the Research and Treatment of Cancer
  • 124. Ex5 Genomics
  • 125. Exagen
  • 126. Excilone
  • 127. ExonHit Therapeutics
  • 128. Exosome Diagnostics
  • 129. Five Prime Therapeutics
  • 130. Flagship Biosciences
  • 131. Foundation Medicine
  • 132. Freenome
  • 133. Gencurix
  • 134. GeneCast Biotechnology
  • 135. GeneCentric Therapeutics
  • 136. Genentech
  • 137. General Biologicals
  • 138. Geneseq Biosciences
  • 139. Geneuity
  • 140. GENEWIZ
  • 141. GENFIT
  • 142. Genomictree
  • 143. Genoptix
  • 144. Genosity
  • 145. Genostics
  • 146. GLAS
  • 147. GOG Foundation
  • 148. Guangzhou Wondfo Biotech
  • 149. Guangzhou Kingmed Diagnostics Group
  • 150. Guardant Health
  • 151. HalioDx
  • 152. Halozyme Therapeutics
  • 153. Hangzhou Normal University
  • 154. Watson Biotech
  • 155. Hematogenix
  • 156. HistoGeneX
  • 157. HistologiX
  • 158. Hologic
  • 159. Horizon Discovery
  • 160. HTG Molecular Diagnostics
  • 161. Hummingbird Diagnostics
  • 162. Hutchison MediPharma
  • 163. ICON
  • 164. IDbyDNA
  • 165. Illumina
  • 166. ImaginAb
  • 167. ImmusanT
  • 168. IncellDx
  • 169. Incyte
  • 170. Inotrem
  • 171. Inovio Pharmaceuticals
  • 172. Insight Genetics
  • 173. Inspirata
  • 174. IntegraGen
  • 175. Intelligent OMICS
  • 176. Interpace Biosciences
  • 177. Invivoscribe
  • 178. IQVIA
  • 179. Janssen Biotech
  • 180. Keen Eye
  • 181. Lab21
  • 182. LabCorp
  • 183. LC Sciences
  • 184. Leica Biosystems
  • 185. Lineagen
  • 186. Lipomics Technologies
  • 187. Locus Biosciences
  • 188. Loxo Oncology
  • 189. Lucence Diagnostics
  • 190. Luminex
  • 191. LungLife AI
  • 192. Macrogen
  • 193. MacroGenics
  • 194. MD Biosciences
  • 195. MDNA Life Sciences
  • 196. MDxHealth
  • 197. MedCDx
  • 198. MedGenome
  • 199. Medical & Biological Laboratories
  • 200. Medivation
  • 201. MEDx(Suzhou) Translational Medicine
  • 202. Memorial Sloan Kettering Cancer Center
  • 203. Menarini Silicon Biosystems
  • 204. Merck
  • 205. Metanomics Health
  • 206. MetaStat
  • 207. Mission Bio
  • 208. MolecularMD
  • 209. Mount Sinai Health System
  • 210. multimmune
  • 211. Myriad Genetic
  • 212. NAMSA
  • 213. NanoString Technologies
  • 214. Natera
  • 215. Navigate BioPharma
  • 216. NEO New Oncology
  • 217. NeoGenomics
  • 218. Nodality
  • 219. N-of-One
  • 220. Novartis Pharmaceuticals
  • 221. Novodiax
  • 222. Novogene
  • 223. NSABP Foundation
  • 224. NuvOx Pharma
  • 225. Ocean Ridge Biosciences
  • 226. OmniSeq
  • 227. Oncimmune
  • 228. Onyx Pharmaceuticals
  • 229. OPKO Health
  • 230. Orbit Genomics
  • 231. Osmetech
  • 232. OWL Metabolomics
  • 233. Oxford BioTherapeutics
  • 234. PamGene International
  • 235. Panacea Pharma
  • 236. PANAGENE
  • 237. Pangaea Oncology
  • 238. Paragon Genomics
  • 239. ParagonDx
  • 240. PAREXEL
  • 241. ParkwayHealth Laboratory
  • 242. PerkinElmer
  • 243. Personal Genome Diagnostics
  • 244. Pfizer
  • 245. PharmaMar
  • 246. Phoenix Molecular Designs
  • 247. Pierre Fabre
  • 248. Plexpress
  • 249. Pharmaceutical Product Development
  • 250. Precision for Medicine
  • 251. PrimeraDx
  • 252. Progenika Biopharma
  • 253. Prognomix
  • 254. ProMedDx
  • 255. Promega
  • 256. Prometheus
  • 257. Provista Diagnostics
  • 258. Psomagen
  • 259. Psynova Neurotech
  • 260. Puma Biotechnology
  • 261. Q2 Solutions
  • 262. QED Therapeutics
  • 263. QIAGEN
  • 264. QualTek
  • 265. Quanterix Corporation
  • 266. Quest Diagnostics
  • 267. Randox Laboratories
  • 268. RareCyte
  • 269. R-Biopharm
  • 270. Regulus Therapeutics
  • 271. Renalytix AI
  • 272. ResearchDx
  • 273. Resolution Bioscience
  • 274. Resonance Health
  • 275. ResourcePath
  • 276. RiboMed Biotechnologies
  • 277. Ridge Diagnostics
  • 278. Riken Genesis
  • 279. Roche
  • 280. SAGA Diagnostics
  • 281. Saladax Biomedical
  • 282. Seegene
  • 283. Sheba Medical Center
  • 284. Shionogi
  • 285. Shuwen Biotech
  • 286. Siemens Healthineers
  • 287. Simcere Diagnostics
  • 288. Singulex
  • 289. Sirius Genomics
  • 290. SkylineDx
  • 291. SomaLogic
  • 292. SOPHiA GENETICS
  • 293. Source BioScience
  • 294. Spectrum Pharmaceuticals
  • 295. SRL Diagnostics
  • 296. Sundance Diagnostics
  • 297. Sysmex Inostics
  • 298. Takeda Pharmaceutical
  • 299. TcLand Expression
  • 300. Tempus
  • 301. Tepnel Pharma Services
  • 302. The Intelligent Tissue Group
  • 303. Theradex Oncology
  • 304. TheragenEtex Bio Institute
  • 305. Theranosis Life Sciences
  • 306. Theranostics Health
  • 307. Thermo Fisher Scientific
  • 308. TIB Molbiol
  • 309. Tosoh Bioscience
  • 310. Transgenomic
  • 311. Translational Research in Oncology
  • 312. TrimGen
  • 313. Tymora Analytical Operations
  • 314. uBiome
  • 315. UC San Diego Medical Center
  • 316. UgenTec
  • 317. UmanDiagnostics
  • 318. Unilabs
  • 319. Vertex Pharmaceuticals
  • 320. Vivia Biotech
  • 321. Vortex Biosciences
  • 322. Wave Life Sciences
  • 323. WuXi NextCODE